Market Overview

UPDATE: Jefferies Raises PT on Eli Lilly & Co. as Least-Preferred Name

Share:
Related LLY
Carl Icahn's Track Record In Big Pharma
After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?
Truxima Fires The Starting Gun In Biosimilar Race To The Bottom (Seeking Alpha)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated an Underperform rating on Eli Lilly & Co. (NYSE: LLY), and slightly raised the price target from $43.00 to $44.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Eli Lilly & Co. closed on Tuesday at $56.74.

Latest Ratings for LLY

DateFirmActionFromTo
Dec 2016Morgan StanleyUpgradesEqual-WeightOverweight
Nov 2016Atlantic EquitiesDowngradesOverweightNeutral
Nov 2016BMO CapitalDowngradesOutperformMarket Perform

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

View Comments and Join the Discussion!